Alkermes Plc (ALKS):企業の財務・戦略的SWOT分析

◆英語タイトル:Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH5650FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Alkermes Plc (ALKS) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Alkermes Plc (Alkermes) is a biopharmaceutical company that focuses on the research, development, and commercialization of drugs for the treatment of cancer, neurodegenerative and central nervous system (CNS) diseases. The company’s proprietary products include Aristada and Aristada Initio an extended-release intramuscular injectable suspension for the treatment of schizophrenia; and Vivitrol, a once-monthly, non-addictive, injectable medication for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence. It also grants license under its proprietary technologies to enable third parties to develop, commercialize and manufacture products. Alkermes sells its products primarily to pharmaceutical wholesalers, treatment providers, specialty distributors and pharmacies. Alkermes is headquartered in Dublin, Ireland.

Alkermes Plc Key Recent Developments

Mar 25,2021: Alkermes Investor Day to Focus on Scientific Progress and Value Creation Strategy
Feb 11,2021: Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021
Feb 11,2021: Alkermes reports financial results for the fourth quarter and year ended Dec. 31, 2020 and provides financial expectations for 2021
Feb 04,2021: Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results
Jan 06,2021: Alkermes announces updates to executive leadership team

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Alkermes Plc – Key Facts
Alkermes Plc – Key Employees
Alkermes Plc – Key Employee Biographies
Alkermes Plc – Major Products and Services
Alkermes Plc – History
Alkermes Plc – Company Statement
Alkermes Plc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Alkermes Plc – Business Description
Product Category: Aristada/Aristada Initio
Overview
Performance
Product Category: Vivitrol
Overview
Performance
Geographical Segment: Ireland
Performance
Geographical Segment: Rest of World
Performance
Geographical Segment: The US
Performance
R&D Overview
Alkermes Plc – Corporate Strategy
Alkermes Plc – SWOT Analysis
SWOT Analysis – Overview
Alkermes Plc – Strengths
Alkermes Plc – Weaknesses
Alkermes Plc – Opportunities
Alkermes Plc – Threats
Alkermes Plc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Alkermes Plc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 25, 2021: Alkermes Investor Day to Focus on Scientific Progress and Value Creation Strategy
Feb 11, 2021: Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2020 and Provides Financial Expectations for 2021
Feb 11, 2021: Alkermes reports financial results for the fourth quarter and year ended Dec. 31, 2020 and provides financial expectations for 2021
Feb 04, 2021: Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results
Jan 06, 2021: Alkermes announces updates to executive leadership team
Dec 11, 2020: Alkermes, Syneos Health, Neuro-Behavioral Clinical Research, Depression Bipolar and Support Alliance, and Matthew Shapiro Win the STARR Coalition STARR of Excellence 2020 Awards
Dec 10, 2020: Alkermes announces strategic value enhancement plan and continued board refreshment
Oct 29, 2020: Alkermes reports third quarter 2020 financial results and raises 2020 financial expectations
Jul 29, 2020: Alkermes reports second quarter 2020 financial results and issues 2020 financial expectations
Jun 29, 2020: Alkermes announces launch of 3rd annual Alkermes pathways research awards program
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Alkermes Plc, Key Facts
Alkermes Plc, Key Employees
Alkermes Plc, Key Employee Biographies
Alkermes Plc, Major Products and Services
Alkermes Plc, History
Alkermes Plc, Other Locations
Alkermes Plc, Subsidiaries
Alkermes Plc, Key Competitors
Alkermes Plc, Ratios based on current share price
Alkermes Plc, Annual Ratios
Alkermes Plc, Annual Ratios (Cont...1)
Alkermes Plc, Interim Ratios
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Alkermes Plc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Alkermes Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Alkermes Plc (ALKS):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Integrity Applications Ltd-医療機器分野:企業M&A・提携分析
    Summary Integrity Applications Ltd (Integrity Applications) is a medical device company that designs, develops and commercializes non-invasive glucose monitoring devices. The company offers glucose monitoring devices and is used in ultrasonic, electromagnetic and thermal technologies to (non-invasiv …
  • Electric Power Development Co Ltd:発電所・企業SWOT分析
    Electric Power Development Co Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Poxel SA (POXEL):企業の財務・戦略的SWOT分析
    Summary Poxel SA (Poxel) is a biopharmaceutical company that focuses to develop drugs for metabolic diseases. The company’s pipeline product portfolio includes Imeglimin, which is developed to target mitochondrial dysfunction, for the treatment of type 2 diabetes; PXL065, a mitochondrial pyruvate ca …
  • Oasis Petroleum Inc. (OAS)-石油・ガス分野:企業M&A・提携分析
    Summary Oasis Petroleum Inc. (Oasis Petroleum) is an independent exploration and production company. It focuses on the acquisition and development of unconventional oil and natural gas resources. The company operates in the Williston Basin in North Dakota and Montana, which consists of project areas …
  • Union Jack Oil plc (UJO):企業の財務・戦略的SWOT分析
    Summary Union Jack Oil Plc (Union Jack Oil), formerly Union Jack Oil Ltd is an onshore oil and gas company that offers exploration and development of hydrocarbon projects. The company develops its portfolio of oil and gas assets by acquiring interests in drill ready prospects. It holds license inter …
  • Steel Connect, Inc. (STCN):企業の財務・戦略的SWOT分析
    Steel Connect, Inc. (STCN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Quest Diagnostics Inc (DGX):企業の財務・戦略的SWOT分析
    Quest Diagnostics Inc (DGX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Ondine Biomedical Inc:企業の製品パイプライン分析2018
    Summary Ondine Biomedical Inc (Ondine), formerly Ondine Biopharma Corp, a subsidiary of 0902337 B.C. Ltd, is a non-antibiotic anti-infective therapies developer for bacterial, viral, and fungal infections. The company’s products include periowave systems, MRSAid systems, sinuwave systems, exelume sy …
  • Banco de Sabadell SA:企業の戦略・SWOT・財務情報
    Banco de Sabadell SA - Strategy, SWOT and Corporate Finance Report Summary Banco de Sabadell SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Landesbank Hessen Thueringen Girozentrale:企業の戦略・SWOT・財務情報
    Landesbank Hessen Thueringen Girozentrale - Strategy, SWOT and Corporate Finance Report Summary Landesbank Hessen Thueringen Girozentrale - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Schuler AG:企業の戦略・SWOT・財務情報
    Schuler AG - Strategy, SWOT and Corporate Finance Report Summary Schuler AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • MCB Bank Ltd:企業の戦略・SWOT・財務情報
    MCB Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary MCB Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • SuanFarma SA:製薬・医療:M&Aディール及び事業提携情報
    Summary SuanFarma SA (SuanFarma Group) is a drug development company that offers production, development, and marketing of raw materials and finished dosage forms. The company’s products portfolio includes amoxiciline capsules, enalapril tablets, colistin methanesulphonate, azitromicine film coated …
  • 3M India Limited (3MINDIA):企業の財務・戦略的SWOT分析
    3M India Limited (3MINDIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Reinhart FoodService L.L.C.:企業の戦略・SWOT・財務分析
    Reinhart FoodService L.L.C. - Strategy, SWOT and Corporate Finance Report Summary Reinhart FoodService L.L.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • CellSeed Inc (7776):企業の財務・戦略的SWOT分析
    Summary CellSeed Inc (CellSeed) is a developer of regenerative medicine. The company’s products include epithelial cell sheet for corneal regeneration, regenerated cardiac patch, epithelial cell sheet for esophageal regeneration, cell sheet for periodontal tissue regeneration and regenerated cartila …
  • Centrais Eletricas Brasileiras S.A. (ELET6):電力:M&Aディール及び事業提携情報
    Summary Centrais Eletricas Brasileiras S.A. (Eletrobras) is an electric utility. It generates, transmits, and distributes energy. The company produces electricity from hydro, nuclear, wind, natural gas, oil, coal, solar, and biomass sources. Eletrobras promotes the Latin American electric integratio …
  • Deckers Outdoor Corporation (DECK):企業の財務・戦略的SWOT分析
    Deckers Outdoor Corporation (DECK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • E.ON UK Plc:企業の戦略的SWOT分析
    E.ON UK Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • ING Groep NV:戦略・SWOT・企業財務分析
    ING Groep NV - Strategy, SWOT and Corporate Finance Report Summary ING Groep NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆